London: The British Prime Minister, Boris Johnson, said the vaccines developed by the University of Oxford and AstraZeneca were much cheaper. In addition, this vaccine will also be easier to store and transport than other vaccines that will be on the market soon.
“The AstraZeneca vaccine, part of its funding comes from taxes paid by British citizens and collaborating with great British companies,” Johnson said, in an accepted statement. Medcom.id, Wednesday, November 25, 2020.
“The price of this vaccine is affordable, easy to use, and very effective,” he added.
<!–
<!–
–
–
–
–
– –>
What do you think of this article?
–
–
In a University of Oxford statement, the vaccine has shown that it can reduce viral transmission from a reduction in asymptomatic infections. The vaccine they are developing, so far there have been no reports of side effects to hospitalization in the volunteers.
“These findings suggest that we have an effective vaccine that will save many lives. Interestingly, we found that one of our dosing rules, about 90 percent proved effective,” said Oxford Vaccine Group Director and Head of Oxford Vaccine Trials Investigator, Professor. Andrew Pollard.
“If this dosing regime is used, there will be more people who can be vaccinated with the planned vaccine supply,” he exclaimed.
The Oxford vaccine (ChAdOx1 nCoV-19) is made from a virus, which is a weak version of the common cold virus (adenovirus), which has been genetically altered so that it is highly unlikely that the virus will grow in humans.
The adenovirus vaccine has been researched and used extensively for decades and has significant benefits because it is stable, easy to produce and transport, and can be stored locally in refrigerator temperatures of 2 to 8 degrees Celsius.
This means that the vaccine can be easily distributed using existing medical facilities such as the doctor’s operating room and the local pharmacy, allowing this vaccine, if approved, to be used very quickly.
This vaccine has been in clinical trials in the UK, Brazil and South Africa since April. Further trials are currently being carried out in the United States, Kenya, Japan and India.
Large-scale vaccine production is currently underway in more than 10 countries to support equitable global access. A key element of Oxford’s partnership with AstraZeneca is a shared commitment to provide vaccines to all people of the world during a pandemic without profit.
These commitments, Pollard said, will continue as long as necessary for low- and middle-income countries.
(FJR)
– .
